The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Stem Cell Therapy Contract Manufacturing Market, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    August 2019

  • Pages
    320

  • View Count
    5723

Example Insights

stem cell company Context stem cell company Types of stem cell therapies stem cell company CMOs
stem cell company Market Opportunity Assesment stem cell company Capacity analysis stem cell company Partnerships & collaborations
stem cell company Manufacturing market stem cell company Forecast analysis  

 

Overview

Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements.Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. Infact, the demand for these contract manufacturing services is likely to be fueled by the increase in number of stem cell therapies being developed for treatment of COVID-19. For instance, stem cell therapy developers such as Athersys and Lattice Biologics have already taken initiatives to find solutions to the fight the novel Coronavirus outbreak.

Scope of the Report

The “Stem Cell Therapies Contract Manufacturing Market, 2019 – 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs. Amongst other elements, the report includes:

  • A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). 
  • An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions.
  • Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook. 
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership.
  • An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).
  • A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies.
  • An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Arik Hasson, Executive VP Research and Development, Kadimastem
  • Brian Dattilo Manager of Business Development, Waisman Biomanufacturing
  • David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota
  • Fiona Bellot, Business Development Manager, Roslin Cell Therapies  
  • Gilles Devillers, General Manager, Bio Elpida
  • Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the stem cell therapy contract manufacturing market in the mid to long term. 

Chapter 3 provides a brief introduction to the basic concepts related to stem cell therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the disease indications targeted by such interventions. It also includes a discussion on the different manufacturing models (centralized and decentralized) that are used for the production of stem cell therapies, along with a list of advantages and disadvantages. Further, it provides details on the scalability of stem cell therapies. The chapter also includes a brief overview on the role of automation and supply chain management, with respect to stem cell therapies.

Chapter 4 provides a comprehensive overview of the global stem cell therapy contract manufacturing landscape. It includes information related to over 80 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogeneic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). In addition, the chapter presents a list of the in-house players involved in manufacturing of stem cell therapies.

Chapter 5 provides a detailed description on the regulatory landscape related to stem cells and cell therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Further, it presents an analysis of the manufacturing facilities on the basis of certifications awarded (for contract manufacturing stem cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in emerging regions such as Europe and Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 8 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2015. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreement, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 presents a detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. The chapter presents a list of stem cell therapies along with other details, such as stage of development, source of stem cell therapy and location of the developer. 

Chapter 10 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of stem cell therapy products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, and large CMOs) in the market, using data from both secondary and primary research. The results of this analysis were used to establish an informed opinion on the stem cell therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 11 features an illustrative view on the demand for stem cell therapies (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of stem cell therapy manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of stem cell therapies that have been registered since 2010. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, leading industry / non-industry sponsors, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the commercialized stem cell products, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 13 features an analysis on the key performance indicators of service providers based on the information available for top-ten (based on the annual revenues generated in 2017)

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion on the stem cell therapies contract manufacturing market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of stem cell therapy contract manufacturing market.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy contract manufacturing domain. We have inputs from Arik Hasson (Executive VP Research and Development, Kadimastem), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), Gilles Devillers (General Manager, Bio Elpida) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. Chapter Overview
3.2. Stem Cell Therapies
3.2.1. Classification of Stem Cells
3.2.1.1. Based on Stem Cell Potency
3.2.1.2. Based on Stem Cell Origin
3.2.1.3. Based on Stem Cell Source
3.2.2. Application of Stem Cell Therapies
3.2.3. Administration of Stem Cells Therapies
3.2.4. Commercialized Stem Cell Therapies
3.3. Stem Cell Therapy Supply Chain
3.3.1. Donor Eligibility and Selection
3.3.2. Sample Collection
3.3.3. Manufacturing
3.3.4. Logistics
3.3.5. Patient Verification and Treatment
3.4. Stem Cell Therapy Manufacturing
3.4.1. Type of Manufacturing Models
3.4.1.1. Centralized Manufacturing Model
3.4.1.2. Decentralized Manufacturing Model
3.4.2. Scalability of Manufacturing Process
3.4.2.1. Scale-Up
3.4.2.2. Scale-Out
3.4.3. Important Factors for Stem Cell Therapy Manufacturing
3.4.3.1. Characterization
3.4.3.2. Cost of Goods
3.4.4. Automation of Stem Cell Therapy Manufacturing
3.4.5. Stem Cell Therapy Contract Manufacturing
3.4.5.1. Need for Outsourcing
3.4.5.2. Advantages of Outsourcing Manufacturing Services
3.4.5.3. Basic Guidelines for Selecting a CMO Partner
3.4.6. Key Challenges and Drivers of the Stem Cell Contract Manufacturing Market

4 MARKET OVERVIEW
4.1. Chapter Overview
4.2. Stem Cell Therapy CMOs: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Types of Services Offered
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Type and Source of Stem Cells
4.3. Stem Cell Therapy CMOs: List of Non-Industry Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Location of Headquarters
4.3.3. Analysis by Location of Manufacturing Facilities
4.3.4. Analysis by Types of Services Offered
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Types and Source of Stem Cells
4.4. Stem Cell Therapies: In-House Manufacturers

5 REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory System in North America
5.2.2. Regulatory System in Europe
5.2.3. Regulatory System in Japan
5.2.4. Conditional Approvals
5.3. Accreditations for Cell Therapy Manufacturing
5.3.1. Information on Facility Approvals Granted by Various Regulatory Authorities
5.4. Guidelines for Manufacturing Cell-based Therapies
5.5. Existing Challenges
5.5.1. Variability in Regulatory Guidelines across Different Geographies

6 STEM CELL THERAPY CONTRACT MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview

6.2. FUJIFILM Cellular Dynamics
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Manufacturing Capabilities and Facilities
6.2.4. Recent Developments and Future outlook

6.3. GenCure
6.3.1. Company Overview
6.3.2. Manufacturing Capabilities and Facilities
6.3.3. Recent Developments and Future outlook

6.4. Progenitor Cell Therapy (PCT)
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Manufacturing Capabilities and Facilities
6.4.4. Recent Developments and Future outlook

6.5. Waisman Biomanufacturing
6.5.1. Company Overview
6.5.2. Manufacturing Capabilities and Facilities
6.5.3. Recent Developments and Future outlook

6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Manufacturing Capabilities and Facilities
6.6.4. Recent Developments and Future Outlook

7 STEM CELL THERAPY CONTRACT MANUFACTURERS IN EUROPE AND ASIA-PACIFIC
7.1. Chapter Overview
7.2. Key Player in Europe

7.2.1. BioNTech Innovative Manufacturing Services
7.2.1.1. Company Overview
7.2.1.2. Manufacturing Capabilities and Facilities
7.2.1.3. Recent Developments and Future Outlook

7.2.2. Cell and Gene Therapy Catapult
7.2.2.1. Company Overview
7.2.2.2. Manufacturing Capabilities and Facilities
7.2.2.3. Recent Developments and Future Outlook

7.2.3. Lonza
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Manufacturing Capabilities and Facilities
7.2.3.4. Recent Developments and Future Outlook

7.2.4. Roslin Cells
7.2.4.1. Company Overview
7.2.4.2. Manufacturing Capabilities and Facilities
7.2.4.3. Recent Developments and Future Outlook

7.3. Key Player in Asia Pacific
7.3.1. MEDINET
7.3.1.1. Company Overview
7.3.1.2. Manufacturing Capabilities and Facilities
7.3.1.3. Recent Developments and Future Outlook
7.3.2. Nikon CeLL innovation
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Manufacturing Capabilities and Facilities
7.3.2.4. Recent Developments and Future Outlook

8 PARTNERSHIPS AND COLLABORATION
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapy Contract Manufacturing: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Stem Cells
8.3.4. Analysis by Source of Stem Cells
8.3.5. Analysis by Scale of Operation
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Regional Analysis
8.3.7.1. Intercontinental and Intracontinental Agreements

9 THERAPY DEVELOPERS AND CMOs: REGIONAL ANALYSIS
9.1. Chapter Overview
9.2. Stem Cell Therapies and Developers
9.3. Therapy Developers and CMOs in North America
9.3.1. CMOs Offering Services for Preclinical Stage Molecules: North America
9.3.2. CMOs Offering Services for Clinical Stage Molecules: North America
9.3.3. CMOs Offering Services for Commercialized Molecules: North America
9.4. Therapy Developers and CMOs in Europe
9.4.1. CMOs Offering Services for Preclinical Molecules: Europe
9.4.2. CMOs Offering Services for Clinical Molecules: Europe
9.4.3. CMOs Offering Services for Commercialized Molecules: Europe
9.5. Therapy Developers and CMOs in Asia Pacific / RoW
9.5.1. CMOs Offering Services for Preclinical Molecules: Asia Pacific / RoW
9.5.2. CMOs Offering Services for Clinical Stage Molecules: Asia Pacific / RoW
9.5.3. CMOs Offering Services for Commercialized Molecules: Asia Pacific / RoW

10 CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology

10.3. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Number of Cleanrooms
10.3.1. Analysis by Size of the CMO
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Region

10.4. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Area of Cleanrooms
10.4.1. Analysis by Size of the CMO
10.4.2. Analysis by Scale of Operation
10.4.3. Analysis by Region
10.5. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Number of Cleanrooms
10.5.1. Analysis by Scale of Operation
10.5.2. Analysis by Region
10.6. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Area of Cleanrooms
10.6.1. Analysis by Scale of Operation
10.6.2. Analysis by Region
10.7. Conclusion

11 DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Clinical Demand for Stem Cell Therapy Manufacturing
11.3.1. Analysis by Types of Stem Cells
11.3.2. Analysis by Source of Stem Cells
11.3.3. Analysis by Geographical Location
11.4. Global Commercial Demand for Stem Cell Therapy Manufacturing
11.4.1. Analysis by Types of Stem Cells
11.4.2. Analysis by Source of Stem Cells
11.4.3. Analysis by Geographical Location

12 MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030
12.4. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells
12.5. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells
12.6. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
12.7. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size
12.8. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography

12.8.1. Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030
12.8.1.1. Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030
12.8.1.2. Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.1.3. Stem Cell Therapy Contract Manufacturing Market in North America For Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.1.4. Stem Cell Therapy Contract Manufacturing Market in North America For Allogeneic Stem Cell Therapies, 2019-2030
12.8.1.5. Stem Cell Therapy Contract Manufacturing Market in North America For Autologous Stem Cell Therapies, 2019-2030
12.8.1.6. Stem Cell Therapy Contract Manufacturing Market in North America, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.1.7. Stem Cell Therapy Contract Manufacturing Market in North America, for Commercial Scale Operations, 2019-2030
12.8.1.8. Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030
12.8.1.9. Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030
12.8.1.10. Stem Cell Therapy Contract Manufacturing Market in North America for Large Companies, 2019-2030

12.8.2. Stem Cell Therapy Contract Manufacturing in Europe, 2019-2030
12.8.2.1. Stem Cell Therapy Contract Manufacturing in Europe for Adult Stem Cell-based Therapies, 2019-2030
12.8.2.2. Stem Cell Therapy Contract Manufacturing in Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.2.3. Stem Cell Therapy Contract Manufacturing Market in Europe For Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.2.4. Stem Cell Therapy Contract Manufacturing Market in Europe For Allogeneic Stem Cell Therapies, 2019-2030
12.8.2.5. Stem Cell Therapy Contract Manufacturing Market in Europe For Autologous Stem Cell Therapies, 2019-2030
12.8.2.6. Stem Cell Therapy Contract Manufacturing Market in Europe, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.2.7. Stem Cell Therapy Contract Manufacturing Market in Europe, for Commercial Scale Operations, 2019-2030
12.8.2.8. Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030
12.8.2.9. Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030
12.8.2.10. Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030

12.8.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
12.8.3.1. Stem Cell Therapy Contract Manufacturing in Asia and Rest of the World for Adult Stem Cell-based Therapies, 2019-2030
12.8.3.2. Stem Cell Therapy Contract Manufacturing in Market in Asia and Rest of the World for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.3.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.3.4. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Allogeneic Stem Cell Therapies, 2019-2030
12.8.3.5. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Autologous Stem Cell Therapies, 2019-2030
12.8.3.6. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.3.7. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, for Commercial Scale Operations, 2019-2030
12.8.3.8. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030
12.8.3.9. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030
12.8.3.10. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030

13 KEY PERFORMANCE INDICATORS
13.1. Chapter Overview
13.2. Stem Cell Therapy Contract Manufacturers: Key Performance Indicators

13.2.1. Financial Indicators
13.2.1.1. Big Pharma Perspective
13.2.1.2. Contract Manufacturers’ Perspective

13.2.2. Process and Capability Indicators
13.2.2.1. Big Pharma Perspective
13.2.2.2. Contract Manufacturers’ Perspective

13.2.3. Market Reputation Indicators
13.2.3.1. Big Pharma Perspective
13.2.3.2. Contract Manufacturers’ Perspective

13.3. Conclusion

14 CONCLUDING REMARKS
14.1. Chapter Overview
14.2. Key Takeaways

15 EXECUTIVE INSIGHTS
15.1. Chapter Overview

15.2. Bio Elpida
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Gilles Devillers, General Manager

15.3. Kadimastem
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Arik Hasson, Executive VP Research and Development

15.4. RoslinCT
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Fiona Bellot, Business Development Manager

15.5. University of Minnesota
15.5.1. Company Snapshot
15.5.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine

15.6. Waisman Biomanufacturing
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Brian Dattilo, Manager of Business Development

15.7. Yposkesi
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development

16. APPENDIX 1: TABULATED DATA
 
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Evolution of Stem Cell Research
Figure 3.2 Classification of Stem Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 3.4 Key Processes in the Stem Cell Therapies Supply Chain
Figure 3.5 Key Steps Involved in the Manufacturing of Stem Cell Therapies
Figure 3.6 Keys Steps Involved in the Logistic Operations of Autologous Therapies
Figure 3.7 Centralized Manufacturing: Process Model
Figure 3.8 Decentralized Manufacturing: Process Model
Figure 3.9 Types of Contract Manufacturers
Figure 3.10 Key Factors to Consider while Selecting a CMO Partner
Figure 3.11 Stem Cell Therapy: Challenges and Drivers
Figure 4.1 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Figure 4.2 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Figure 4.3 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Figure 4.4 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
Figure 4.5 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Figure 4.6 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
Figure 4.7 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells Used
Figure 4.8 Stem Cell Therapy CMOs (Industry): Distribution by Type of Stem Cells Used
Figure 4.9 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Figure 4.10 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
Figure 4.11 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facility
Figure 4.12 Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
Figure 4.13 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Operation
Figure 4.14 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells
Figure 4.15 Stem Cell Therapy CMOs (Non-Industry): Distribution by Type of Stem Cells Used
Figure 5.1 Stem Cell Therapy Contract Manufacturing: Distribution of Manufacturing Facilities by Regulatory Authorities
Figure 6.1 FUJIFILM Cellular Dynamics: Annual Revenues, 2014- Q1 2019 (JPY Billion)
Figure 6.2 Hitachi Chemical (Progenitor Cell Therapy): Annual Revenues, 2015- Q1 2019 (YEN Billion)
Figure 6.3 WuXi AppTec: Annual Revenues, 2015- 2018 (RMB Million)
Figure 7.1 Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Figure 7.2 Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Type of Partnership and Year (2015-2019)
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 8.5 Partnerships and Collaborations: Distribution by Source of Stem Cells and Type of Partnership
Figure 8.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 8.7 Partnerships and Collaborations: Most Active Players
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Therapy Developers and CMOs in North America
Figure 9.2 Therapy Developers and CMOs in Europe
Figure 9.3 Therapy Developers and CMOs in Asia Pacific / RoW
Figure 10.1 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Figure 10.2 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Figure 10.3 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Company Size (Sample Data Set for Industry Players)
Figure 10.4 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Figure 10.5 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Figure 10.6 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.7 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Figure 10.8 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Figure 10.9 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.10 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Figure 10.11 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Figure 10.12 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.13 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Figure 10.14 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Figure 10.15 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Figure 11.1 Global Clinical Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Figure 11.2 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Figure 11.3 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Figure 11.4 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Figure 11.5 Global Commercial Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Figure 11.6 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Figure 11.7 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Figure 11.8 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Figure 12.1 Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
Figure 12.2 Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
Figure 12.3. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
Figure 12.4 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Scale of Operation, 2019-2030 (USD Million)
Figure 12.5 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Company Size, 2019-2030 (USD Million)
Figure 12.6 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 12.7 Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Figure 12.8 Stem Cell Therapy Contract Manufacturing Market in the US, 2019-2030 (USD Million)
Figure 12.9 Stem Cell Therapy Contract Manufacturing Market in the Canada, 2019-2030 (USD Million)
Figure 12.10 Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.11 Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.12 Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.13 Stem Cell Therapy Contract Manufacturing Market in North America for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.14 Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.15 Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.16 Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Figure 12.17 Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.18 Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.19 Stem Cell Therapy Contract Manufacturing Market in North America for Large Companies, 2019-2030 (USD Million)
Figure 12.20 Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Figure 12.21 Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Figure 12.22 Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
Figure 12.23 Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Figure 12.24 Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Figure 12.25 Stem Cell Therapy Contract Manufacturing Market Rest of Europe, 2019-2030 (USD Million)
Figure 12.26 Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.27 Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.28 Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.29 Stem Cell Therapy Contract Manufacturing Market in Europe for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.30 Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.31 Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.32 Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Figure 12.33 Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.34 Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.35 Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
Figure 12.36 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
Figure 12.37 Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Figure 12.38 Stem Cell Therapy Contract Manufacturing Market in Rest of Asia-Pacific, 2019-2030 (USD Million)
Figure 12.39 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.40 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.41 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 13.42 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.43 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.44 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.45 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Commercial Scale Operations, 2019-2030 (USD Million)
Figure 12.46 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.47 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.48 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030 (USD Million)

Figure 13.1 Stem Cell Therapy Contract Manufacturers: Key Performance Indicators (KPIs)
Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.3 Financial Indicators: Big Pharma Perspective
Figure 13.4 Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.5 Process / Capability Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.6 Process / Capability Indicators: Big Pharma Perspective
Figure 13.7 Process / Capability Indicators: Contract Manufacturers’ Perspective
Figure 13.8 Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.9 Market Reputation Indicators: Big Pharma Perspective
Figure 13.10 Market Reputation Indicators: Contract Manufacturers’ Perspective

List of Tables

Table 3.1 Differences between Stem Cell Therapies and Biotechnology Products
Table 3.2 Stem Cell Therapies: Approved Products,
Table 3.3 Assessment Strategies for Different Manufacturing Processes
Table 3.4 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 4.1 Stem Cell Therapy Contract Manufacturers: List of Industry Players
Table 4.2 Stem Cell Therapy Contract Manufacturers: List of Industry Players
Table 4.3 Stem Cell Therapy CMOs: Information on Type of Services Offered (Industry Players)
Table 4.4 Stem Cell Therapy CMOs: Information on Scale of Operation (Industry Players)
Table 4.5 Stem Cell Therapy CMOs: Information on Type and Source of Stem Cells Used (Industry Players)
Table 4.6 Stem Cell Therapy Contract Manufacturers: List of Non-Industry Players
Table 4.7 Stem Cell Therapy CMOs: Information on Type of Services Offered (Non-Industry Players)
Table 4.8 Stem Cell Therapy CMOs: Information on Scale of Operation (Non-Industry Players)
Table 4.9 Stem Cell Therapy CMOs: Information on Type and Source of Stem Cells Used (Non-Industry Players)
Table 4.10 Stem Cell Therapies: List of In-House Manufacturers
Table 5.1 Stem Cell Therapy Manufacturing: Regulatory Authorities
Table 5.2 Cell Therapy: Regulatory Considerations
Table 6.1 Stem Cell CMOs: List of Profiled Companies in North America
Table 6.2 FUJIFILM Cellular Dynamics: Company Overview
Table 6.3 FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
Table 6.4 FUJIFILM Cellular Dynamics: Recent Development and Future Outlook
Table 6.5 GenCure: Company Overview
Table 6.6 GenCure: Overview of Manufacturing Capabilities
Table 6.7 GenCure: Recent Development and Future Outlook
Table 6.8 Progenitor Cell Therapy: Company Overview
Table 6.9 Progenitor Cell Therapy: Overview of Manufacturing Capabilities
Table 6.10 Progenitor Cell Therapy: Recent Development and Future Outlook
Table 6.11 Waisman Biomanufacturing: Company Overview
Table 6.12 Waisman Biomanufacturing: Overview of Manufacturing Capabilities
Table 6.13 Waisman Biomanufacturing: Recent Development and Future Outlook
Table 6.14 WuXi Advanced Therapies: Company Overview
Table 6.15 WuXi Advanced Therapies: Overview of Manufacturing Capabilities
Table 6.16 WuXi Advanced Therapies: Recent Development and Future Outlook
Table 7.1 Stem Cell CMOs: List of Profiled Companies in Europe and Asia
Table 7.2 BioNTech Innovative Manufacturing Services: Company Overview
Table 7.3 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
Table 7.4 BioNTech Innovative Manufacturing Services: Recent Development and Future Outlook
Table 7.5 Cell and Gene Therapy Catapult: Company Overview
Table 7.6 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
Table 7.7 Company Cell and Gene Therapy Catapult: Recent Development and Future Outlook
Table 7.8 Lonza: Company Overview
Table 7.9 Lonza: Overview of Manufacturing Capabilities
Table 7.10 Lonza: Recent Development and Future Outlook
Table 7.11 RoslinCT: Company Overview
Table 7.12 RoslinCT: Overview of Manufacturing Capabilities
Table 7.13 RoslinCT: Recent Development and Future Outlook
Table 7.14 MEDINET: Company Overview
Table 7.15 MEDINET: Overview of Manufacturing Capabilities
Table 7.16 MEDINET: Recent Development and Future Outlook
Table 7.17 Nikon CeLL innovation: Company Overview
Table 7.18 Nikon CeLL innovation: Overview of Manufacturing Capabilities
Table 7.19 Nikon CeLL innovation: Recent Development and Future Outlook
Table 8.1 Stem Cell Therapy Contract Manufacturing: Partnerships and Collaborations, 2015-2019
Table 9.1 List of Stem Cell Therapies and their Developers
Table 9.2 CMOs Offering Services for Preclinical Stage Molecules: North America
Table 9.3 CMOs Offering Services for Clinical Stage Molecules: North America
Table 9.5 CMOs Offering Services for Preclinical Molecules: Europe
Table 9.6 CMOs Offering Services for Clinical Molecules: Europe
Table 9.8 CMOs Offering Services for Preclinical Molecules: Asia Pacific / RoW
Table 9.9 CMOs Offering Services for Clinical Stage Molecules: Asia Pacific / RoW
Table 10.1 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
Table 10.2 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 10.3 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 10.4 Stem Cell Therapy Installed Manufacturing Capacity in Terms of Area of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 10.5 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Average Capacity
Table 10.6 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms (Non-Industry): Average Capacity
Table 15.1 Bio Elpida: Key Highlights
Table 15.2 Kadimastem: Key Highlights
Table 15.3 RoslinCT: Key Highlights
Table 15.4 University of Minnesota: Key Highlights
Table 15.5 Waisman Biomanufacturing: Key Highlights
Table 15.6 Yposkesi: Company Snapshot
Table 16.1 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Table 16.2 Stem Cell Therapy CMOs (Industry): Distribution by Size of Employee Base
Table 16.3 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Table 16.4 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
Table 16.5 Stem Cell Therapy CMOs (Industry): Distribution by Type of Services Offered
Table 16.6 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
Table 16.7 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells Used
Table 16.8 Stem Cell Therapy CMOs (Industry): Distribution by Type of Stem Cells Used
Table 16.9 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Table 16.10 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters (Region-wise)
Table 16.11 Stem Cell Therapy CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 16.12 Stem Cell Therapy CMOs: Distribution by Type of Services Offered
Table 16.13 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Operation
Table 16.14 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells Used
Table 16.15 Stem Cell Therapy CMOs (Non-Industry): Distribution by Type of Stem Cells Used
Table 16.16 Stem Cell Therapy Contract Manufacturing: Distribution of Manufacturing Facilities by Regulatory Authorities
Table 16.17 FUJIFILM Cellular Dynamics: Annual Revenues, 2012-Q1 2019 (JPY Billion)
Table 16.18 Hitachi Chemical (Progenitor Cell Therapy): Annual Revenues, 2015- Q1 2019 (YEN Billion)
Table 16.19 WuXi AppTec: Annual Revenues, 2015- 2018 (RMB Million)
Table 16.20 Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Table 16.21 Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
Table 16.22 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Table 16.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2019)
Table 16.25 Partnerships and Collaborations: Distribution by Type of Stem Cells
Table 16.26 Partnerships and Collaborations: Distribution by Source of Stem Cells and Type of Partnership
Table 16.27 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 16.28 Partnerships and Collaborations: Most Active Players
Table 16.29 Partnership and Collaborations: Regional Distribution
Table 16.30 Contract Manufacturing Opportunity Assessment in North America
Table 16.31 Contract Manufacturing Opportunity Assessment in Europe
Table 16.32 Contract Manufacturing Opportunity Assessment in Asia Pacific / RoW
Table 16.33 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Table 16.34 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Table 16.35 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Company Size (Sample Data Set for Industry Players)
Table 16.36 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Table 16.37 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Table 16.38 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.39 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Table 16.40 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Table 16.41 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Table 16.42 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Table 16.43 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Table 16.44 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.45 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Table 16.46 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Table 16.47 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.48 Global Clinical Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Table 16.49 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Table 16.50 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Table 16.51 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Table 16.52 Global Commercial Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Table 16.53 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Table 16.54 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Table 16.55 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Table 16.56 Overall Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
Table 16.57 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
Table 16.58 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
Table 16.59 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
Table 16.60 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size (USD Million)
Table 16.61 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
Table 16.62 Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Table 16.63 Stem Cell Therapy Contract Manufacturing Market in US, 2019-2030 (USD Million)
Table 16.64 Stem Cell Therapy Contract Manufacturing Market in Canada, 2019-2030 (USD Million)
Table 16.65 Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.66 Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.67 Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.68 Stem Cell Therapy Contract Manufacturing Market in North America for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.69 Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.70 Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Table 16.71 Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Table 16.72 Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Table 16.73 Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.74 Stem Cell Therapy Contract Manufacturing Market in North America For Large Companies, 2019-2030 (USD Million)
Table 16.75 Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Table 16.76 Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Table 16.77 Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
Table 16.78 Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Table 16.79 Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Table 16.80 Stem Cell Therapy Contract Manufacturing Market in Rest of the Europe, 2019-2030 (USD Million)
Table 16.81 Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.82 Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.83 Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.84 Stem Cell Therapy Contract Manufacturing Market in Europe for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.85 Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.86 Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Table 16.87 Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Table 16.88 Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Table 16.89 Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.90 Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
Table 16.91 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The Europe, 2019-2030 (USD Million)
Table 16.92 Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Table 16.93 Stem Cell Therapy Contract Manufacturing Market in Rest of The World, 2019-2030 (USD Million)
Table 16.94 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.95 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.96 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.97 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.98 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.99 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Table 16.100 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Commercial Scale Operations, 2019-2030 (USD Million)
Table 16.101 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Table 16.102 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.103 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030 (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report:

  1. 3P Biopharmaceuticals
  2. AbbVie
  3. Accellta
  4. Adaptimmune
  5. Advancecells
  6. Advanced Cell Technology
  7. Aegle Therapeutics
  8. Aelan Cell Technologies
  9. AGC 
  10. Ajinomoto
  11. Ajinomoto Kohjin Bio
  12. AllCells
  13. Allele Biotechnology & Pharmaceuticals
  14. Alpine BioTherapeutics
  15. American CryoStem
  16. Anagenesis Biotechnologies
  17. Andalusian Initiative for Advanced Therapies
  18. Angel Biotechnology
  19. Anterogen
  20. apceth Biopharma
  21. Aspire Health Science
  22. Astellas Pharma
  23. Asterias Biotherapeutics
  24. AstraZeneca
  25. Athersys
  26. Atlantic Bio GMP
  27. Avid Bioservices
  28. Axcelead Drug Discovery Partners
  29. Axiogenesis
  30. Baxter International
  31. Bellicum Pharmaceuticals
  32. Ben-Gurion University of the Negev
  33. Bio Elpida
  34. BioCardia
  35. Bioinova
  36. BioIVT
  37. BioLife Cell Bank
  38. Biological and Cellular GMP Manufacturing Facility, City of Hope
  39. BioNTech IMFS
  40. BioRestorative Therapies
  41. bluebird bio
  42. BlueRock Therapeutics
  43. Bone Therapeutics
  44. BrainStorm Cell Therapeutics
  45. Caladrius Biosciences
  46. Capicor Therapeutics
  47. CardioCell
  48. CardioCreate
  49. Case Western Reserve University School of Medicine
  50. Cell and Gene Therapy Catapult
  51. Cell Cure Neurosciences
  52. Cell Source 
  53. Cell Tech Pharmed
  54. Cell Therapies
  55. Cell Therapy and Regenerative Medicine, University of Utah
  56. Cell Therapy Manufacturing Cooperative Research Centre
  57. Cellect Biotechnology
  58. Cellerant Therapeutics
  59. CELLforCURE
  60. CELLINK
  61. CellProthera
  62. Cells for Sight, Stem Cell Therapy Research Unit, University College London 
  63. Cellular Biomedicine Group
  64. Cellular Therapy Core, University of Texas
  65. Celther Polska
  66. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  67. Center for Cell and Gene Therapy, Baylor College of Medicine
  68. Center for Molecular Medicine Cologne
  69. Center for Specialised Care & Research
  70. Centre for Cell and Vector Production (CCVP)
  71. Centre of Excellence for Cellular Therapy 
  72. Chiesi Farmaceutici 
  73. Clean Cells
  74. ClinImmune Labs
  75. CMC Biologics
  76. Cognate BioServices
  77. Colorado Center for Reproductive Medicine (CCRM) 
  78. Cook MyoSite
  79. Corestem
  80. Creative Medical Technology Holdings
  81. Cryosite
  82. Cryoviva Biotech 
  83. CSL Behring
  84. Cynata Therapeutics
  85. Cytopeutics
  86. Cytori Therapeutics
  87. Daiichi Sankyo
  88. Dendreon
  89. Digilab
  90. DiscGenics
  91. Duke University School of Medicine
  92. Eli Lilly
  93. Emory Personalized Immunotherapy Core
  94. ExCellThera
  95. Exopharm
  96. Fate Therapeutics
  97. Fibrocell
  98. Florey Institute of Neuroscience and Mental Health
  99. Fraunhofer Institute for Cell Therapy and Immunology
  100. FUJIFILM Cellular Dynamics
  101. FUJIFILM Irvine Scientific
  102. Gamida Cell  
  103. Gates Biomanufacturing Facility 
  104. GE Healthcare
  105. GenCure
  106. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  107. Genxbio
  108. Genzyme Biosurgery
  109. Global Cell Med
  110. Global Stem Cells and Regenerative Medicine Acceleration Center
  111. Grace Century
  112. Guy's and St Thomas' Facility
  113. Gwo XI Stem Cell Applied Technology
  114. Harvard Stem Cell Institute, Harvard University
  115. Healios
  116. Helocyte
  117. HemoGenyx Pharmaceuticals 
  118. Hemostemix
  119. Histocell
  120. Histogen
  121. Holostem Terapie Avanzate
  122. Ichor Therapeutics
  123. ID Pharma
  124. Institute of Liver & Biliary Sciences
  125. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami 
  126. International Stem Cell Corporation
  127. iPS Academia Japan
  128. IQVIA Stem Cell Center
  129. Japan Tissue Engineering
  130. Japanese Society for Regenerative Medicine
  131. John Goldman Centre for Cellular Therapy
  132. Johnson & Johnson
  133. Kadimastem
  134. Kangstem Biotech
  135. KBI Biopharma
  136. Kohjin-Bio
  137. Kolon Life Sciences
  138. Kyoto University
  139. Kyushu University
  140. Laboratory for Cell and Gene Medicine, University of Stanford
  141. Life Stem Genetics
  142. Lifecells
  143. LifeSouth Community Blood Centers
  144. Living Cell Technologies
  145. Longeveron
  146. Lonza
  147. Magenta Therapeutics
  148. MaSTherCell
  149. Medeor Therapeutics
  150. MEDINET
  151. Medipost
  152. Merck
  153. Mesoblast
  154. Michael J Fox Foundation for Parkinson's Research
  155. Molecular and Cellular Therapeutics, University of Minnesota
  156. Moraga Biotechnology
  157. Morphogenesis
  158. Nanion Technologies
  159. National Eye Institute
  160. Nature Cell
  161. Neovii 
  162. Nestlé Institute of Health Sciences
  163. Neuralstem
  164. NeuroGen Brain & Spine Institute
  165. NeuroGeneration
  166. New York Blood Center
  167. NHS Blood and Transplant (NHSBT)
  168. NIHR GOSH Biomedical Research Centre
  169. Nikon CeLL innovation
  170. Nohla Therapeutics
  171. Novadip Biosciences
  172. Novartis
  173. Ocata Therapeutics
  174. Octane Biotech
  175. OhioHealth
  176. OiDE BetaRevive
  177. Orchard Therapeutics
  178. Organogenesis
  179. Orgenesis
  180. Orisis Therapeutics
  181. Personalized Stem Cells
  182. Pfizer
  183. PharmaCell
  184. Pharmicell
  185. Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  186. Pluristem Therapeutics
  187. Progenitor Cell Therapy (PCT)
  188. Promethera Biosciences
  189. Protide Pharmaceuticals
  190. Provia Laboratories
  191. Rayne Cell Therapy Suite, King's College London
  192. Regeneris Medical
  193. Regeneus
  194. ReNeuron 
  195. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  196. RHEACELL
  197. Roche
  198. ROHTO Pharmaceutical
  199. RoosterBio
  200. RoslinCT
  201. Roswell Park Cancer Institute
  202. Royal Free Hospital
  203. Samsung BioLogics
  204. SanBio
  205. Saneron CCEL Therapeutics
  206. Sangamo Therapeutics
  207. S-Biomedic
  208. Sclnow Biotechnology
  209. SCM Lifescience
  210. Scottish National Blood Transfusion Service (SNBTS)
  211. Sentien Biotechnologies
  212. SeouLin Bioscience
  213. Shanghai Biotechnology 
  214. Sistemic
  215. SSM Health Cardinal Glennon Children's Hospital
  216. Stem Cell Theranostics
  217. Stem Cells Arabia
  218. StemBioSys
  219. STEMCELL Technologies
  220. Stemedica Cell Technologies
  221. StemGenn Therapeutics
  222. Steminent Biotherapeutics
  223. Stemline Therapeutics
  224. Stemmatters 
  225. StemoniX
  226. Stempeutics Research
  227. Taiga Biotechnologies
  228. Taiwan Bio Therapeutics
  229. Takara Bio
  230. Takeda Pharmaceutical
  231. Terumo
  232. Theracell
  233. Tianhe Stem Cell Biotechnologies
  234. Tianjin Ever Union Biotechnology
  235. TiGenix
  236. Tissue Genesis
  237. TreeFrog Therapeutics
  238. U.S. Stem Cell
  239. UC Davis GMP Laboratory
  240. UC Irvine Medical Center 
  241. UCI Beall Applied Innovation
  242. Universal Cells
  243. University Hospitals Case Medical Center
  244. University of California
  245. University of Manchester
  246. University of Newcastle
  247. Upstate Stem Cell cGMP Facility, University of Rochester
  248. Vecura, Karolinska University Hospital
  249. Vericel
  250. ViaCyte
  251. Viscofan
  252. Viscofan BioEngineering
  253. Vor Biopharma
  254. Waisman Biomanufacturing
  255. Worldwide Clinical Trials
  256. WuXi Advanced Therapies
  257. Xcelthera
  258. Xellbiogene
  259. YposKesi

Segmentation

The USD 2.5 billion (by 2030) financial opportunity within the stem cells contract manufacturing market has been analyzed across the following segments:

  • Scale of Operation
    • Preclinical 
    • Clinical
    • Commercial
  • Size of Contract Manufacturer 
    • Small-sized
    • Mid-sized
    • Large / Very Large
  • Source of Stem Cells
    • Autologous
    • Allogenic
  • Type of Stem Cells
    • Adult
    • Embryonic
    • Induced Pluripotent 
  • Key geographical regions 
    • North America (US)
    • Europe (UK, France, Germany, Italy and Spain)
    • Asia (Japan)
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com